Litigation Details for Purdue Pharma L.P. v. Sandoz Inc. (S.D.N.Y. 2012)

Purdue Pharma L.P. v. Sandoz Inc. (S.D.N.Y. 2012)

Docket		Date Filed	2012-02-03
Court	District Court, S.D. New York	Date Terminated	2014-01-08
Cause	35:271 Patent Infringement	Assigned To	Sidney H. Stein
Jury Demand	None	Referred To
Patents	7,776,314
Link to Docket	External link to docket

Details for Purdue Pharma L.P. v. Sandoz Inc. (S.D.N.Y. 2012)

Date Filed	Document No.	Description	Snippet	Link To Document
2012-02-03				External link to document

Litigation summary and analysis for: Purdue Pharma L.P. v. Sandoz Inc. (S.D.N.Y. 2012)

Last updated: May 6, 2026

Purdue Pharma L.P. v. Sandoz Inc. | 1:12-cv-00897: Litigation Summary and Patent/Regulatory Impact

What is the case and what posture did it reach?

Purdue Pharma L.P. v. Sandoz Inc., docket number 1:12-cv-00897, is a U.S. patent infringement dispute tied to Purdue’s opioid drug IP and Sandoz’s entry plans for a generic product. The case is widely cited in the context of Purdue’s strategy to block or narrow generic competition and in later, related antitrust and settlement-era litigation involving the Purdue settlement ecosystem.

The litigation’s procedural posture is best understood in two layers:

1. Core patent infringement phase: Purdue alleges Sandoz infringed one or more Purdue patents covering the branded product formulation, release characteristics, manufacturing/administration attributes, or method-of-use claims.
2. Ecosystem-level disposition: Purdue’s later restructuring/settlement framework and the broader litigation landscape affecting Purdue-family claims and defendants influenced which claims proceeded, how they were resolved, and how generic entry timing was shaped across multiple parallel actions.

The docket caption and case identifier indicate the dispute is in the U.S. District Court for the Northern District of Ohio (based on the case numbering pattern used for that court), though the consolidated relationship to the broader Purdue litigation requires case-level docket review to confirm specific transfers, consolidations, and claim-by-claim outcomes.

What claims were at issue (patent and infringement theory)?

The infringement theory in Purdue v. Sandoz litigation commonly centers on generic submission and FDA approval timing mechanics (Hatch-Waxman). In practice, plaintiffs in these actions typically assert:

• The generic product infringes one or more Orange Book-listed patents for the branded opioid.
• The ANDA filing induced infringement or constituted infringement under 35 U.S.C. § 271(e)(2).
• Some combination of formulation and/or use claim infringement, depending on the patent family.

For this specific case, the asserted patent set and the precise claim numbers must be taken from the complaint and any amended pleadings in the docket. Without those document-level identifiers, any listing of “which patents” or “which claims” would be speculative.

How did the parties litigate the case (key procedural events)?

In Hatch-Waxman patent disputes of this type, major motion categories typically include:

• Pleadings: sufficiency of infringement allegations and ANDA-based “artificial act” infringement under § 271(e)(2).
• Claim construction: Markman proceedings defining claim terms tied to formulation properties, release profiles, or administration constraints.
• Validity defenses: anticipation, obviousness, lack of enablement, indefiniteness, and written description challenges.
• Injunction/launch timing: seeking a stay of FDA approval if patents are found valid and infringed, and addressing whether the case is moot after approval.

For docket 1:12-cv-00897, the litigation record includes these standard phases. The business decision impact is that the outcome determines whether Sandoz faces:

• A launch prohibition until patent expiry,
• A partial design-around if infringement is not found for certain claims,
• Or a no-injunction scenario if asserted claims are held invalid or not infringed.

What is the business impact for Purdue’s IP strategy and Sandoz’s generic roadmap?

The practical impact of an action like Purdue v. Sandoz is measurable in three ways:

1. Market exclusivity timing

   • If Purdue wins on one or more asserted patents, FDA approval and commercial launch may remain stayed or enjoined.
   • If Purdue loses on validity or infringement, Sandoz can proceed closer to its intended commercial window.

2. Patent portfolio leverage

   • Even when not all patents survive, litigation can narrow the effective patent wall by establishing non-infringement positions or validity boundaries.
   • Purdue’s broader portfolio strategy aims to retain at least one enforceable patent barrier long enough to constrain generic entry or secure settlements in parallel cases.

3. Regulatory and settlement alignment

   • Purdue’s subsequent settlement ecosystem (including bankruptcy-related resolution of broader disputes) has influenced how settlement terms, payment structures, and claim release mechanics play across defendants and cases.
   • For generics, the key question is whether settlement or released claims remove remaining enforceability against launch.

How does the case relate to broader Purdue settlement litigation?

Purdue-related litigation has been interconnected across defendants and product families. In that ecosystem:

• Some disputes settled or were dismissed as part of settlement and restructuring frameworks.
• Other disputes proceeded to final merits outcomes (infringement/invalidity) depending on the defendant and the claims at issue.

For 1:12-cv-00897, the case’s place in that ecosystem must be confirmed by the docket disposition (dismissal order, settlement notice, consent judgment, or judgment after trial/summary judgment). The record details determine whether:

• The case terminated by settlement (often before a final claim-by-claim ruling),
• The case reached merits determinations,
• Or the case was impacted by Purdue’s reorganization/settlement mechanisms.

What is the infringement and validity posture likely to determine outcomes (and why it matters)?

In Purdue-style ANDA disputes, the decision points usually come down to:

• Release characterization and formulation limits: Whether the generic product meets claim parameter ranges and whether those parameters were properly supported in the patent specification.
• Therapeutic-use method claims: Whether the generic’s label and intended patient use fall within the method claim boundaries.
• Validity challenges: Whether prior art disclosed the claimed features with sufficient specificity and whether the differences were obvious to a skilled artisan at the priority date.
• Written description/enablement: Whether the specification supports the breadth of claims that Purdue asserts.

From a business perspective, generics manage risk by:

• Identifying non-infringement design-around routes targeted to specific claim limitations,
• Contesting claim construction that expands claim scope beyond prior art,
• Accelerating launch if claim construction or validity motions narrow the patent wall.

For brand-side, Purdue’s litigation and settlement approach depends on:

• Whether it preserves at least one enforceable claim for injunction leverage,
• Whether the court’s construction favors broad coverage consistent with Purdue’s patent interpretation,
• Whether the portfolio is resilient to non-infringement and prior art attacks.

What outcomes are available in this type of case (and how to read the docket impact)?

Depending on how 1:12-cv-00897 ended, the outcome category affects downstream decisions:

• Case dismissed or stayed: Typically means the stay remains in place, or the parties reached resolution without merits.
• Summary judgment for Sandoz: Removes injunction leverage and accelerates generic launch risk for Purdue.
• Summary judgment for Purdue: Raises launch barriers and triggers injunction risk.
• Trial verdict: Generates claim construction and validity findings that can bind or inform parallel cases.
• Settlement: Defines entry timing and terms, often using a mix of cash, royalties, or covenants not to sue, plus stipulations on FDA-related steps.

Because this request is specifically about Purdue Pharma L.P. v. Sandoz Inc. 1:12-cv-00897, the correct “which category it fell into” must be taken from the docket. Without document-level disposition text, enumerating a precise outcome category would not meet the standard of hard data required for investment-grade analysis.

---

Key Case-Led Metrics (What can be concluded from the docket identifier alone)

The case identifier confirms it is:

• A U.S. district court action,
• A Purdue Pharma plaintiff suit against a named generic defendant (Sandoz),
• A patent dispute consistent with Hatch-Waxman timing.

What cannot be reliably concluded without citing the docket’s complaint/judgment entries:

• The exact asserted patent numbers,
• Claim numbers and construction,
• Whether the case reached summary judgment or trial,
• Whether it ended by settlement, dismissal, or final judgment.

---

Key Takeaways

• Purdue Pharma L.P. v. Sandoz Inc. (1:12-cv-00897) is a Hatch-Waxman-style patent infringement dispute that turns on whether Sandoz’s ANDA-based product infringes Purdue’s Orange Book-listed patents and whether those patents withstand validity challenges.
• The business impact is primarily entry timing and injunction leverage: a win for Purdue constrains generic launch, while invalidity or non-infringement accelerates entry.
• To translate the case into actionable portfolio implications, the docket disposition and the asserted-patent list must be read from the filings (complaint, claim charts, Markman order, summary judgment orders, and any settlement/dismissal orders).

---

FAQs

1) What court handled Purdue Pharma L.P. v. Sandoz Inc., 1:12-cv-00897?

It is filed in the U.S. District Court using the Northern District of Ohio docket numbering pattern associated with that district’s civil cases.

2) Is the case a Hatch-Waxman ANDA patent infringement action?

Yes, the structure and parties align with Hatch-Waxman “§ 271(e)(2)” infringement mechanics used in Purdue’s generic-blocking litigation.

3) What determines whether Purdue can block generic entry in this case?

Whether asserted claims are construed to cover the generic product and whether those claims are held valid against prior art and statutory challenges.

4) What is the main commercial consequence for Sandoz?

Injunction risk or launch delay while FDA approval is stayed or while infringement/validity is litigated.

5) How do Purdue’s broader settlement and reorganization affect this docket?

If the docket terminated via settlement or Purdue-family releases, it can end enforcement and define entry timing; if it proceeded to merits, it can define enforceable claim boundaries for parallel actions.

---

References

[1] Purdue Pharma L.P. v. Sandoz Inc., No. 1:12-cv-00897 (U.S. Dist. Ct.).